Avid Bioservices Inc (CDMO)

[Protector]

cj, this article is full of errors.

1) No third arm in SUNRISE

The trial is again pitching bavituximab against Docetaxel, with a 3rd

placebo arm thrown in.

2) Bavituximab does NOT bind to the PS receptors it binds the PS the ligand

Essentially, the drug binds to receptors on the surface of cancerous cells

3) Bavituximab doesn't signal the immune system, it blocks PS from suppressing it. It does however stimulate the activation of the immune system in second order.

...and signals the immune system to come and attack endothelial cells.